Evaluation of the Clinical Efficacy of Chuzhi Shengfa Tablets and Finasteride in the Treatment of Androgenetic Alopecia

Objective: To explore the clinical efficacy and safety of Chuzhi Shengfa tablets combined with finasteride in the treatment of male androgenetic alopecia (AGA). Methods: Sixty male patients with androgenetic alopecia admitted to our Department of Dermatology between January 2022 and January 2024 were randomly divided into two groups, with 30 patients in each group. The control group was treated with finasteride, while the observation group received a combination of Chuzhi Shengfa tablets and finasteride. The clinical efficacy and adverse reactions in both groups were compared. Results: The overall effectiveness rate in the observation group was 93.33% (28/30), significantly higher than the control group’s 73.33% (22/30), with a statistically significant difference (P < 0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion: The combination of Chuzhi Shengfa tablets and finasteride shows good clinical efficacy in treating male androgenetic alopecia. Additionally, Chuzhi Shengfa tablets are convenient to administer and effectively improve efficacy, significantly improving patients’ conditions, and demonstrating good clinical application value.